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la Med́iterraneé and Universite ́ de Provence, Aix-Marseille Universite,́ Case 925, 163 Avenue de Luminy, Marseille 3288 CEDEX 9,
France
¶Department of Pharmaceutical Chemistry, Faculty of Life Sciences, University of Vienna, Althanstraße 14, Vienna A-1090, Austria
⊥Unite ́ des Virus Emergents, UVE: Aix-Marseille Univ-IRD 190-Inserm 1207-IHU Med́iterraneé Infection, 13385 Marseille,
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ABSTRACT: Enteroviruses (family Picornaviridae) comprise a large group of human pathogens against which no licensed
antiviral therapy exists. Drug-repurposing screens uncovered the FDA-approved drug ﬂuoxetine as a replication inhibitor of
enterovirus B and D species. Fluoxetine likely targets the nonstructural viral protein 2C, but detailed mode-of-action studies are
missing because structural information on 2C of ﬂuoxetine-sensitive enteroviruses is lacking. We here show that broad-spectrum
anti-enteroviral activity of ﬂuoxetine is stereospeciﬁc concomitant with binding to recombinant 2C. (S)-Fluoxetine inhibits with
a 5-fold lower 50% eﬀective concentration (EC50) than racemic ﬂuoxetine. Using a homology model of 2C of the ﬂuoxetine-
sensitive enterovirus coxsackievirus B3 (CVB3) based upon a recently elucidated structure of a ﬂuoxetine-insensitive
enterovirus, we predicted stable binding of (S)-ﬂuoxetine. Structure-guided mutations disrupted binding and rendered
coxsackievirus B3 (CVB3) resistant to ﬂuoxetine. The study provides new insights into the anti-enteroviral mode-of-action of
ﬂuoxetine. Importantly, using only (S)-ﬂuoxetine would allow for lower dosing in patients, thereby likely reducing side eﬀects.
KEYWORDS: antiviral, enteroviruses, drug repurposing, virus replication, molecular modeling
The genus Enterovirus within the Picornaviridae familyincludes many medically and socioeconomically impor-
tant pathogens, which are among the most common infections
in mankind. Four enterovirus (EV) species (EV-A, -B, -C, and
-D) and three rhinovirus (RV) species (RV-A, -B, and -C)
include serotypes that are known to cause human infections,
like poliovirus, coxsackie A and B viruses, echoviruses,
numbered enteroviruses (e.g., EV-A71 and EV-D68), and
rhinovirus. Infections with enteroviruses can cause a broad
spectrum of diseases ranging from hand-foot-and-mouth
disease to conjunctivitis, aseptic meningitis, severe neonatal
sepsis-like disease, and acute ﬂaccid paralysis, whereas
infections with rhinoviruses cause the common cold as well
as exacerbations of asthma and chronic obstructive pulmonary
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disease (COPD).1 These viral infections are often self-limiting
but can also result in severe complications especially in young
children. To date, no antiviral therapy to treat enterovirus
infections has been approved and treatment remains limited to
supportive care. Worldwide vaccination campaigns have almost
eradicated poliomyelitis. However, the vaccines against polio-
virus and a recently approved EV-A71 vaccine in China are
currently the only ones developed against enteroviruses.
Vaccination is likely not a feasible general strategy to prevent
enterovirus infections given the enormous amount (>250) of
enterovirus (sero)types. Hence, the development of broad-
spectrum anti-enteroviral drugs could be a promising
alternative.
Enteroviruses are small, nonenveloped, positive-sense,
single-stranded RNA viruses with an icosahedral capsid. The
genome of ∼7.5 kb encodes a single polyprotein that is
autoprocessed into structural proteins (VP1, VP2, VP3, and
VP4), nonstructural proteins (2A, 2B, 2C, 3A, 3B, 3C, and
3D), and several functional processing intermediates. The viral
nonstructural proteins, particularly the protease 3Cpro and the
RNA-dependent RNA polymerase 3Dpol, are attractive targets
for antiviral drug development.2
The viral protein 2C is the most conserved nonstructural
protein among picornaviruses, which makes it particularly
interesting for broad-spectrum anti-enteroviral drug design.
The viral 2C protein functions as ATPase,3−5 ATPase-
dependent RNA helicase, and an ATPase-independent RNA
chaperone;6 all of these enzymatic functions are indispensable
for the viral life cycle. The ATPase domain of the protein
belongs to the superfamily of SF3 helicases of the AAA+
ATPases and contains Walker A and Walker B motifs and
motif C.7 Besides the ATPase domain, 2C harbors an N-
terminal membrane-associated helical domain, a cysteine-rich
motif, and putative RNA binding motifs. 2C has been
implicated in pleiotropic functions such as uncoating,8 cellular
membrane rearrangement,9−12 RNA binding,13−15 RNA
replication,16−21 immune evasion,22 and encapsidation.23−26
Although 2C has a central role in the viral life cycle, the exact
details of its involvement remain poorly understood.
Over the past decades, structurally disparate 2C inhibitors
such as guanidine hydrochloride (GuaHCl), 2-(α-hydroxyben-
zyl)-benzimidazole HBB, MRL-1237, and TBZE-029 have
been identiﬁed.2,27−30 An emerging concept to discover new
antivirals is drug repurposing. This strategy oﬀers an attractive
alternative to de novo drug development, as profound
pharmacological and toxicological proﬁles of the compounds
are already available. Furthermore, when the repurposed drug
can be used at a similar dosage as for the original indication, it
may directly enter phase 2 clinical trials,31,32 thereby reducing
development cost and time. Several drug-repurposing screens
have uncovered FDA-approved drugs as inhibitors of enter-
ovirus replication.2 Some of these compounds are thought to
inhibit the nonstructural protein 2C because nonsynonymous
resistance mutations occur in 2C. Fluoxetine (Prozac), a
selective serotonin reuptake inhibitor (SSRI) that is FDA-
approved for the treatment of major depression and anxiety
disorders, was identiﬁed as a potent inhibitor of EV-B and -D
species but EV-A, EV-C, or rhinovirus species remained
unaﬀected.33−35 Besides its anti-enteroviral activity, ﬂuoxetine
was also shown to inhibit dengue virus and hepatitis C virus,
two members of the Flaviviridae family, where it likely acts as a
host-targeting rather than a direct-acting antiviral as it is the
case for enteroviruses.36,37 Fluoxetine has already been
successfully used to treat an immunocompromised child with
life-threatening chronic enterovirus encephalitis,38 underscor-
ing the potential of ﬂuoxetine for the application as an anti-
Figure 1. Fluoxetine inhibits CVB3 replication in a stereospeciﬁc manner. (A) The two enantiomers of ﬂuoxetine. (B) Multicycle CPE reduction
assay to determine the antiviral activity of ﬂuoxetine enantiomers. HeLa R19 cells were treated with serial dilutions of racemate, (S)-, or (R)-
ﬂuoxetine and infected with coxsackievirus B3 (CVB3) at an MOI of 0.001. In parallel, cells were treated with the compound only to assess
cytotoxicity. After 3 days, cell viability was determined using an MTS assay. Data are from one experiment, representative of at least three
independent experiments. (C) In a single cycle assay, HeLa R19 cells were infected with Renilla luciferase (RLuc)-CVB3 reporter virus and treated
with serial dilutions of racemate, (S)-, or (R)-ﬂuoxetine, and luciferase activity was determined at 7 h post-infection as a quantitative measure of
replication. (D) In parallel, uninfected cells were treated with the compound and cell viability was determined using an MTS assay. Data are from
one experiment, representative of two independent experiments.
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enteroviral compound. Although various 2C inhibitors have
been discovered over the years, their mode-of-action is still
poorly understood.
Here, we set out to investigate how ﬂuoxetine targets 2C of
coxsackievirus B3 (CVB3), a virus model commonly used as a
prototype for enterovirus B species. Fluoxetine has one chiral
center, resulting in 2 enantiomers, and we experimentally
showed that only the S-enantiomer inhibits enterovirus
replication by directly binding to the viral protein 2C. On
the basis of the recently published crystal structure of the
catalytic domain of EV-A71 2C protein,39 a homology model
for the corresponding part of CVB3 2C was generated. Two
pockets ﬂanking a stretch of amino acids that often mutate to
convey resistance against 2C inhibitors (224AGSINA229)
were identiﬁed. Molecular dynamics simulations predicted a
stable interaction for the (S)-ﬂuoxetine in only one of these
pockets. Mutations of residues deep in the predicted binding
pocket confer resistance to ﬂuoxetine and contribute to the
understanding of the antiviral mode-of-action. Thus, we
identiﬁed for the ﬁrst time a putative binding pocket for
antiviral compounds in the nonstructural enterovirus protein
2C.
1. RESULTS
1.1. (S)-Fluoxetine Inhibits CVB3 Replication by
Binding to the Nonstructural Protein 2C. Fluoxetine is
clinically used as a racemic mixture (1:1 enantiomeric ratio),
and both enantiomers are of equal pharmacological activity
toward the serotonin transporter SERT.40 The racemic
compound was identiﬁed in drug-repurposing screens as an
inhibitor of replication of EV-B and EV-D species.33,34 Since
ﬂuoxetine has one chiral center, we investigated the antiviral
properties of both enantiomers (Figure 1A). Coxsackievirus B3
(CVB3), a member of the EV-B genus, causes a readily
observable cytopathic eﬀect (CPE), apparent as rounding,
detachment, and eventually dying of the cell. The racemic
mixture and both enantiomers, purchased from two diﬀerent
vendors (Sigma-Aldrich and Carbosynth), were tested in a
multicycle CPE-reduction assay to elucidate whether the
compounds inhibit virus replication and thereby prevent the
development of CPE. In parallel, cytotoxicity of the
compounds was determined using an calorimetric method
for sensitive quantiﬁcation using the (3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetra-
zolium) salt (MTS).
HeLa R19 cells were infected with CVB3 at a multiplicity of
infection (MOI) of 0.001, which yields complete cell death
within 3 days of incubation. The racemic mixture inhibited
CVB3 with 50% eﬀective concentration (EC50) of 3.2 ± 0.95
μM, while the S-enantiomer inhibited with an EC50 of 0.4 ±
0.15 μM (Figure 1B). In contrast, the R-enantiomer did not
show any protection against CVB3 (Figure 1B). To validate
these ﬁndings in a single cycle assay, HeLa R19 cells were
infected with RLuc-CVB3 and the cells were treated with serial
dilutions of the corresponding compounds. Cells were lysed at
7 h post-infection, and luciferase activity was measured as a
quantitative and sensitive readout for viral replication. At the
same time, cytotoxicity of the compounds was determined with
an MTS assay, and the CC50 of the compounds in HeLa R19
cells ranges from 23 to 28 μM (Table 1). The racemic mixture
and the S-enantiomer exerted antiviral activity with an ∼5-fold
higher potency for the S-enantiomer (EC50 of 0.42 ± 0.17 μM)
compared to the racemic mixture (EC50 of 2.02 ± 0.94 μM)
(Figure 1C). Again, the R-enantiomer did not show an antiviral
eﬀect (Figure 1C,D).
1.2. Antiviral Eﬀect of (S)-Fluoxetine against Other
Enteroviruses. Previously, it was shown that the racemic
mixture of ﬂuoxetine inhibits enterovirus B and D replication
prototyped by CVB3 (strain Nancy) and EV-D68 (strain
Fermon).33,34 As the S-enantiomer is more active toward
CVB3 than the racemic mixture, we reassessed the antiviral
activity of (S)-ﬂuoxetine against a panel of enteroviruses. As
expected, the racemic mixture is only active against enterovirus
B and D, e.g., CVB3 and EV-D68 (strain Fermon) species
(Table 1).34,41 (S)-Fluoxetine is more potent than the racemic
mixture not only toward CVB3 but also toward EV-D68.
Strikingly, while the racemic mixture does not confer any
antiviral eﬀect against rhinoviruses, the S-enantiomer inhibits
rhinovirus 2 (HRV-2) and HRV-14 replication, with an EC50
of 7.95 ± 0.39 and 6.34 ± 1.02 μM, respectively (Table 1).
The S-enantiomer was not active against EV-A71 (strain BrCr)
and poliovirus (strain Sabin) at a concentration up to 30 μM.
Higher concentrations could not be reached due to
cytotoxicity of (S)-ﬂuoxetine. We cannot exclude that (S)-
ﬂuoxetine would also inhibit other enteroviruses at higher
concentrations in other systems in which the CC50 is much
higher.
1.3. Fluoxetine Directly Binds to Recombinant 2C
Protein in Vitro. To gain further insights into the ﬂuoxetine
mode-of-action, we next investigated whether it directly binds
to 2C protein. Production and puriﬁcation of full-length 2C
protein usually leads to a polydisperse preparation, which is
problematic for binding assays. By removing the ﬁrst 36 amino
acids of the N-terminus, a homogeneous preparation of
monomeric protein can be obtained and used for binding
assays, namely, thermal shift assay (TSA) and isothermal
titration calorimetry (ITC).35 First, TSA was used to detect a
direct binding of the racemic mixture and the enantiomers of
ﬂuoxetine to CVB3 2C. In this assay, the increase of the
melting temperature (Tm) of the protein reﬂects the binding of
Table 1. Antiviral Activity of Stereoisomers of Fluoxetinea
virus species strain racemate (S)-ﬂuoxetine (R)-ﬂuoxetine SIRacemic SI(S)‑fluoxetine
EV-A71 EV-A BrCr NA NA NA NA NA
CVB3 EV-B Nancy 2.02 ± 0.52 0.42 ± 0.17 NA 14.51 71.56
PV-1 EV-C Sabin1 NA NA NA NA NA
EV-D68 EV-D Fermon 1.85 ± 0.10 0.67 ± 0.22 NA 21.72 42.73
HRV-A2 RV-A NA 7.95 ± 0.39 NA NA 3.60
HRV-B14 RV-B NA 6.34 ± 1.02 NA NA 4.52
CC50 29.32 ± 0.35 28.63 ± 1.02 23.63 ± 1.40
aShown are EC50 and CC50 values in μM. Data represents mean values ± SD calculated from at least three diﬀerent experiments. NA = not active.
SI = selectivity index (CC50/EC50).
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a ligand. The racemic mixture was able to induce a dose-
dependent increase of the Tm of 2C protein in a range of 10 to
250 μM (Figure 2A) while at higher concentrations the Tm
decreased. In contrast, the S-enantiomer of ﬂuoxetine was able
to thermally stabilize the 2C protein in a concentration-
dependent manner (Figure 2A) with no destabilization at high
concentrations of compound, suggestive of a direct binding of
(S)-ﬂuoxetine to the protein. As a positive control, we used
dibucaine, an established 2C inhibitor.35
Interestingly, the R-enantiomer appeared to have a
destabilizing eﬀect on the protein at high concentrations
(Figure 2A). The unexpected pattern of the racemic mixture
may be explained by the collective eﬀects of (S)-ﬂuoxetine
(stabilization) and (R)-ﬂuoxetine (destabilization). To conﬁrm
these results, we next quantiﬁed the binding of (S)- and (R)-
ﬂuoxetine to 2C protein by ITC. The S-enantiomer bound to
2C with a dissociation equilibrium constant (Kd) of ∼9.5 μM
(Figure 2B). 2C partly aggregated during the titration of (R)-
ﬂuoxetine, in agreement with the results obtained by TSA. It
was therefore not possible to retrieve a precise Kd, but when
ﬁtting the experimental data to a one-site binding model, the
observed Kd was higher than 200 μM (Figure 2B).
Thus, together with the data obtained in the antiviral assay,
binding of (S)-ﬂuoxetine is likely responsible for the 2C-
mediated antiviral eﬀect. However, given the diﬀerence of
binding of (S)-ﬂuoxetine to the recombinant protein (10 μM)
and the EC50 in cell-based assays (<1 μM), oﬀ-target eﬀects
cannot be formally ruled out. Still, (R)-ﬂuoxetine did aﬀect the
2C protein in the TSA and ITC at high concentrations.
Therefore, we investigated whether (R)-ﬂuoxetine can exert
any additional eﬀect on virus replication in combination with
(S)-ﬂuoxetine. To this end, the eﬀect of diﬀerent concen-
trations of (S)-ﬂuoxetine combined with increasing concen-
trations of the R-enantiomer on CVB3 replication was
determined. At high concentrations of (S)-ﬂuoxetine (4 and
10 μM), replication of CVB3 was completely inhibited, and as
expected, no additional eﬀect of (R)-ﬂuoxetine could be
observed (Figure 2C). At low concentrations of (S)-ﬂuoxetine,
CVB3 replication was not impaired, nor could an additional
eﬀect of the R-enantiomer be observed (Figure 2C), in line
with the absence of antiviral activity of (R)-ﬂuoxetine alone
(Figure 1B,C). Strikingly, when cells were treated with the
approximate EC50 concentration of (S)-ﬂuoxetine (0.4 μM),
(R)-ﬂuoxetine exerted a clear dose-dependent inhibition of
Figure 2. (S)-Fluoxetine binds to the nonstructural protein 2C in vitro. (A) The binding of racemate, (S)-, and (R)-ﬂuoxetine to recombinant
CVB3 2C was determined by the thermal shift assay. The thermal stabilization of 2C by racemic and (S)-ﬂuoxetine, represented by an increase in
melting temperature, indicates binding of the compounds to 2C. (B) The binding of (S)- and (R)-ﬂuoxetine to 2C were determined by isothermal
calorimetry. As a positive control, the known 2C inhibitor dibucaine was used.35 Raw data are depicted at the top, and the integrated data are
depicted at the bottom. Data are shown ﬁtted to a one-site binding model. (C) HeLa R19 cells were infected with RLuc-CVB3, and the cells were
treated with a ﬁxed concentration of (S)-ﬂuoxetine combined with serial dilutions of (R)-ﬂuoxetine. Error bars depict standard error of the mean
calculated from biological triplicates. Data are representative of two independent experiments.
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virus replication (Figure 2C). Hence, (R)-ﬂuoxetine can
apparently exert weak antiviral activity that could come from
the destabilization of the 2C protein or from the broad-
spectrum antiviral eﬀect induced by the targeting of a cellular
partner.36,37
1.4. Fragment Screening Identiﬁes Key Parts of
Fluoxetine Involved in Targeting 2C. To gain more
information about which chemical moieties of ﬂuoxetine are
involved in exerting the antiviral activity, we tested six diﬀerent
fragments of ﬂuoxetine (Figure 3A) in a CPE reduction assay
using CVB3. Fragments 1, 2, and 4 were synthesized, whereas
fragments 3, 5, and 6 were purchased and tested as received
without further puriﬁcation. Only fragment 1 showed a weak
antiviral activity in the multicycle assay at concentrations close
to cytotoxic concentrations (Figure 3B). To exclude that
inhibition of the virus is caused by an unspeciﬁc cytotoxic
eﬀect, the fragments were also tested in a single cycle assay
using a RLuc-CVB3. HeLa R19 cells were infected with RLuc-
CVB3, treated with 100 or 10 μM of each fragment,
respectively, and luciferase activity at 7 h post-infection was
determined as a quantitative and sensitive readout for virus
replication. In this single cycle assay, fragment 1 showed an
antiviral eﬀect at 100 μM (Supplementary Figure 1A). In
parallel, acute cytotoxicity of the fragments was excluded using
an MTS assay (Supplementary Figure 1B). To further aﬃrm
that the observed weak antiviral activity of fragment 1 is
speciﬁc and not due to cytotoxicity, we tested whether two
other ﬂuoxetine-insensitive viruses were aﬀected by fragment 1.
Cells were infected with EV-A71 or Renilla luciferase-
expressing encephalomyocarditis virus (RLuc-EMCV),42,43
and as positive controls, guanidium chloride (GuaHCl), a
replication inhibitor for EV-A71 and CVB3, and dipyridamole
(DIP), a replication inhibitor for EMCV, were used. The virus
titers and replication were determined by end point titration
and a luciferase assay, respectively. Both viruses were not
inhibited by fragment 1 at 100 μM (Figure 3C), indicating that
the inhibitory eﬀect of fragment 1 on CVB3 replication is
speciﬁc.
Finally, we investigated binding of the ﬂuoxetine fragments
to recombinant 2C using a thermal shift assay (TSA). The
binding of low molecular weight molecules usually has a
moderate eﬀect on protein stability (<1 °C in protein
stabilization), and concentrations should be >100 μM to
observe protein stabilization.44 Therefore, we tested the
fragments in the TSA at a concentration range from 100 to
400 μM. Neither fragment 1 nor any other fragment was able
to stabilize the 2C protein at the indicated concentrations
(Supplementary Figure 1C). At present, we can only speculate
why fragment 1 exerts weak antiviral activity but does not
stabilize 2C in the TSA. Possibly, the amount of recombinant
2C protein in the in vitro assay is higher than in an infection
setting, which would require a higher concentration of the
Figure 3. Fragment screening identiﬁes key parts of ﬂuoxetine involved in targeting 2C. (A) Molecular structures of ﬂuoxetine and the diﬀerent
fragments that were used. (B) The CPE-reduction assay as performed in Figure 1B. (C) HeLa R19 cells were infected with CVB3, EV-A71, or
RLuc-EMCV in order to exclude an unspeciﬁc antiviral eﬀect of fragment 1. The replication inhibitor guanidium chloride (GuaHCl, 2 mM) was
used in the case of CVB3 and EV-A71 as positive control. Dipyridamole (DIP, 100 μM) was used as the positive control replication inhibitor
during RLuc-EMCV infection.
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compound to induce a shift in the melting temperature of 2C.
It can however be noticed that the eﬀect of fragments on Tm is
usually very modest because the binding energy is weak.44
Taken together, fragment 1 was able to inhibit CVB3
replication, but a direct binding could not be observed in the
TSA.
1.5. Identiﬁcation of a Potential Binding Pocket for
Fluoxetine on 2C. After having investigated chemical
properties of ﬂuoxetine that are important for its antiviral
activity, we next wanted to further characterize the possible
intermolecular interactions between (S)-ﬂuoxetine and 2C.
Because structures of 2C of ﬂuoxetine-sensitive viruses were
not available, we resorted to an in silico modeling approach. We
ﬁrst generated a homology model of CVB3 2C (Figure 4A) on
the basis of the crystal structure of a part of 2C of the
ﬂuoxetine-insensitive virus EV-A71.39 The crystallized part of
EV-A71 2C covers amino acids 116−329. In this region, the
sequence identity and similarity between EV-A71 and CVB3
2C is 62% and 80%, respectively.
Enterovirus 2C belongs to a family of AAA+ ATPases, which
oligomerize in hexameric ring structures in which the ATP is
coordinated by two monomers.39 Such ring structures were
observed in low resolution electron microscopy structures of
2C proteins from poliovirus and foot-and-mouth disease virus,
a picornavirus from the aphthovirus genus.45,46 The published
EV-A71 2C structure (PDB: 5GRB) shows a C-terminal
interaction between two adjacent 2C molecules to form a
bipartite binding site for the ATP. In total, there are six protein
chains in the crystal structure of which only chains A and B are
fully resolved, whereas all the others have at least one gap.39
The cocrystallized ATP molecules adopt diﬀerent conforma-
tions for each chain, and only chains A and F crystallize in a
conformation resembling a bipartite binding site with both
monomers forming hydrogen bonds with the ATP. Therefore,
chain A was used as a template to generate the homology
model of CVB3 2C (Figure 4A). Superimposition onto the
EV-A71 2C structure resulted in a CVB3 2C model with a
reasonably good ﬁt and an overall root mean square deviation
(RMSD) of 0.30 Å from the template with the highest
deviation for residues N257 (1.65 Å) and D274 (2.08 Å).
The CVB3 2C homology model was used to search for
pockets in which ﬂuoxetine may bind. Because mutations in
the ﬂexible 224AGSINA229 loop confer resistance to
ﬂuoxetine,34 we focused on pockets near this loop. Two
potential binding pockets ﬂanking the 224AGSINA229 loop
were identiﬁed, termed site A and site B (Figure 4B). Site A
faces away from the ATP binding site and is conﬁned by the
224AGSINA229 loop on one side and hydrophilic residues
(D245, R295, and R296) on the other side. Site A is a deep,
lipophilic pocket, whereas site B is a rather shallow pocket and
lies between the 224AGSINA229 loop and the 175−183 loop,
which is downstream of the Walker B motif. In the crystal
Figure 4. Predicted ﬂuoxetine binding sites on CVB3 2C protein. (A) Homology model of the 2C protein of CVB3 built on the crystal structure of
EV-A71. Ribbon and carbon atoms of the 224AGSINA229 loop are in blue, the 175−183 loop, in violet, and the 158−164 loop, in cyan. (B) S- and
R-enantiomers of ﬂuoxetine docked into sites A and B of the homology model. (C) View of (S)-ﬂuoxetine in site A as identiﬁed in the molecular
dynamics simulations, comprising the residues L126, L178, C179, V187, F190, I227, A229, L238, F242, and D245. The triﬂuoromethyl moiety of
ﬂuoxetine is buried deep inside the hydrophobic pocket. (D) Three possible entrances of (S)-ﬂuoxetine to reach C179 (green line surface).
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structure of EV-A71 and in the CVB3 homology model, both
sites might considerably change their shapes due to loop
movements. However, site A is not aﬀected to the point of
blocking the binding of ﬂuoxetine, while site B is. Both
enantiomers of ﬂuoxetine were docked into each of the two
pockets for further computational investigations (Figure 4B).
In site A, both enantiomers docked in proximity of the residues
A229 and I227 of the 224AGSINA229 loop. The 4-
(triﬂuoromethyl)benzene moiety occupied the hydrophobic
bottom of the pocket consisting of the residues L178, C179,
V187, and F190. Instead, in site B, both enantiomers were
mostly exposed to the solvent.
1.5.1. Molecular Dynamics Simulations Reveal Stable
Positioning of (S)-Fluoxetine in Pocket A. After the selection
of the possible pockets near the AGSINA motif, the binding
sites containing both enantiomers were subjected to molecular
dynamics simulations. The 224AGSINA229 loop is thought to
be ﬂexible, thereby alternating the shape of the two identiﬁed
pockets, resulting in diﬀerent predicted binding modes
compared to the docking. To evaluate the stability of the
ﬂuoxetine enantiomers docked into the pockets and to address
why mutations in this loop can cause resistance toward
ﬂuoxetine, the docking models of (S)-ﬂuoxetine and (R)-
ﬂuoxetine in site A and site B were subjected to molecular
dynamics simulations. For each enantiomer docked into either
site, three independent molecular dynamic simulations of 100
ns were performed. The calculated binding energies of (S)- or
(R)-ﬂuoxetine into site A and site B from the molecular
dynamics simulations are listed in Table 2. The simulations
showed that (S)-ﬂuoxetine bound stronger to 2C than (R)-
ﬂuoxetine in both site A and site B. We observed that (R)-
ﬂuoxetine dissociated from pocket A as well as pocket B in one
of the three independent simulations, suggesting that (R)-
ﬂuoxetine cannot engage in stable interaction with 2C. In site
B, movement of the 224AGSINA229 loop was observed,
making the hydrophobic pocket accessible for the 4-
(triﬂuoromethyl)benzene moiety of ﬂuoxetine. However, visual
inspection and the binding energies of the molecular dynamics
suggested that site A provides a more stable binding pocket for
(S)-ﬂuoxetine, deﬁned by the residues L126, L178, V187,
F190, L238, I227, A229, and F242 (Figure 4C).
In each independent repetition of the molecular dynamics
simulation on (S)-ﬂuoxetine in site A, the compound was
oriented such that the 4-(triﬂuoromethyl)benzene moiety
occupied the hydrophobic pocket (Figure 4C). During the
molecular dynamics simulations, a hydrogen bond repeatedly
formed between the amino acid D245 and the positively
charged amino group of (S)-ﬂuoxetine (Figure 4C). We
conclude, in line with the antiviral data and binding assays
from the in silico approach, that (S)-ﬂuoxetine binds stronger
to 2C than the R-enantiomer. Furthermore, on the basis of our
in silico analyses, we conclude that (S)-ﬂuoxetine most likely
binds 2C to site A.
1.5.2. Mutations in the Identiﬁed Binding Pocket Confer
Resistance to (S)-Fluoxetine. The triple amino acid sub-
stitution A224V−I227V−A229V (AVIVAV) in CVB3 2C,
clustered in the 224AGSINA229 region, was previously shown
to confer resistance to the racemic ﬂuoxetine mixture34 and to
several other 2C inhibitors.29 Likewise, the triple mutant
provided resistance to (S)-ﬂuoxetine (Figure 5A). This
resistance is speciﬁc, as AVIVAV mutations did not confer
resistance to BF738735, a compound that inhibits enterovirus
replication via a diﬀerent mechanism, namely, by targeting the
cellular protein PI4KIIIβ, which is essential for enterovirus
replication.47
To dissect the contribution of the individual mutations to
the resistance, several CVB3 mutant viruses containing the
single mutations A224V, I227V, or A229V were made. The
A224V mutation alone did not confer resistance to the
compounds (Figure 5B). The single mutation I227V provided
a high level of resistance toward (S)-ﬂuoxetine but not the
control compound BF738735 (Figure 5B). This is in
concordance with a recently published report, which raised
resistant mutants toward racemic ﬂuoxetine and identiﬁed the
mutations I227V and N228S.41 The A229V single mutant virus
was previously described to be dependent on all structurally
divergent 2C inhibitors tested (GuaHCl, HBB, TBZE-029, and
MRL-1237),29 meaning that these mutant viruses are not
inhibited by the compounds but instead strictly require them
for eﬃcient replication. Strikingly, the A229V virus was not
dependent on (S)-ﬂuoxetine at the concentration tested
(Figure 5C). To test whether the A229V virus is resistant to
(S)-ﬂuoxetine, we assessed replication in the presence of both
GuaHCl (to allow replication) and (S)-ﬂuoxetine. However,
the A229V mutation does not confer resistance to (S)-
ﬂuoxetine.
To ﬁnd experimental support for the predicted binding
pocket, we next investigated the importance of key residues in
the site A pocket by mutational analysis. We ﬁrst mutated two
amino acids that are located deep within site A and tested
whether they could confer resistance to (S)-ﬂuoxetine. These
mutations are C179F, which, like C179Y, provides resistance
toward several structurally diﬀerent 2C inhibitors,41 and
F190L, which raises resistance to a novel 2C inhibitor.49 In
line with our model, viruses containing the C179F or the
F190L mutation in 2C were highly resistant to (S)-ﬂuoxetine
(Figure 5D). We next investigated two amino acids that are
located near the edge of site A. V187 was substituted by an M,
because the corresponding amino acid 187 in the ﬂuoxetine-
insensitive virus EV-A71 is a methionine and we hypothesized
that this methionine may contribute to the insensitivity of EV-
A71 to ﬂuoxetine. The amino acid D245 displayed repeated
interactions with the positively charged amino group of (S)-
ﬂuoxetine in the molecular dynamics simulations (Figure 4C).
We therefore decided to remove the charge of this residue by
replacing it with asparagine. However, neither the V187 M nor
the D245N mutations provided resistance to (S)-ﬂuoxetine
(Figure 5E), which seems to contradict our computation-based
hypothesis that (S)-ﬂuoxetine binds to site A interacting with
C187 and D245. Fluoxetine may bind in a slightly diﬀerent
Table 2. Binding Energies of the Protein Ligand Complexes
during MD Simulationsa
compound MD1 MD2 MD3
site A (R)-ﬂuoxetine −29.71* −42.70 −19.85*
(S)-ﬂuoxetine −41.63 −42.28 −41.54
site B (R)-ﬂuoxetine −29.59* −42.95 −27.38
(S)-ﬂuoxetine −34.79 −29.88 −30.83*
aValues indicated are calculated ΔGbinding average values over 100 ns
of each of the three independent molecular dynamics simulations
(MD) for the indicated ligands in site A or B (kJ/mol). The most
favorable complex according to the simulations is (S)-ﬂuoxetine in
site A. For all the other complexes in at least one simulation, the
ligand dissociated from the protein (indicated by *).
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conformation within the pocket that does not involve
interactions with these two residues; thus, mutations would
not confer resistance. That would still explain why the C179F
and F190L mutations confer resistance. Alternatively, ﬂuox-
etine may access residues C179 and F190 from a third
entrance site (Site C), schematically depicted in Figure 4D
(cyan arrow), and therefore is unaﬀected by the mutations in
site A and the 224AGSINA229 loop. However, neither in the
homology model nor in the EV-A71 crystal structure does the
supposed site C present an obvious cavity for the potential
ligand entrance toward the residues C179 and F190. Because
of ﬂexibilities in the loops ranging from amino acid residue 158
to 163, 175 to 183, and 224 to 229, other conformations likely
exist so that site C may become accessible. In that case, the
occurrence of mutations in the 224AGSINA229 loop and how
they can confer resistance are more diﬃcult to explain. We
propose the hypothesis that conformational changes over a
longer range could aﬀect the shape of the pocket, and
therefore, slight changes in the distant 224AGSINA229 loop
might be suﬃcient to convey resistance. Clearly, actual
crystallographic data of (S)-ﬂuoxetine bound to 2C is needed
to deﬁnitively resolve this point.
Figure 5. Mutations in the identiﬁed binding pocket confer resistance toward (S)-ﬂuoxetine. (A) HeLa R19 cells were infected with WT CVB3 or
the AVIVAV mutant (A224V−I227V−A229V triple mutant) at an MOI of 0.1 and treated with 1 μM (S)-ﬂuoxetine or 1 μM BF738735 as a
control replication inhibitor that acts via the host protein PI4KBIIIβ.48 Eight hours post-infection, cells were freeze−thawed and virus titers were
determined by end point titration. Means and standard deviations were calculated from biological triplicates. (B) The individual A224V and I227V
mutations were tested for resistance toward (S)-ﬂuoxetine as in (A). (C) The guanidine chloride-dependent virus A229V was tested for
dependency on (S)-ﬂuoxetine. Experiments were performed similar to those in (A). Because the A229V virus is dependent on GuaHCl, sensitivity
to the inhibitors was also tested in the presence of 1 mM GuaHCl (blocked bars). (D) Residues in the hydrophobic binding pocket were mutated
(C179F and F190L) and tested for resistance toward (S)-ﬂuoxetine as in (A). (E) Residues at the surface of the hydrophobic binding pocket
(V187 M and D245N) were substituted in the Renilla luciferase virus, and sensitivity to (S)-ﬂuoxetine was determined as in Figure 1C. (F) The
binding of (S)-ﬂuoxetine to recombinant WT CVB3 2C or 2C harboring the resistance mutations C179F, I227V, and A229V was tested using the
thermal shift assay as in Figure 2A. In all panels, data are shown from one experiment representative of at least two independent experiments. Error
bars depict the standard error of the mean calculated from biological triplicates.
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Finally, we wanted to address whether resistance mutations
in 2C aﬀect binding of (S)-ﬂuoxetine to 2C. Recombinant 2C
proteins harboring the resistance mutations I227V or C179F
or the A229V mutation were produced, and binding was tested
by TSA (Figure 5F). (S)-Fluoxetine was not able to stabilize
any of the mutated 2C proteins from thermal denaturation,
implying that the substitutions abrogated ﬂuoxetine binding to
2C. Unexpectedly, the C179F substitution made 2C more
sensitive to thermal denaturation in the presence of (S)-
ﬂuoxetine when compared to the C179F mutant without
compound (ΔTm of −2.5 °C). The A229V substitution
nulliﬁed thermal stabilization of 2C by (S)-ﬂuoxetine,
suggesting that this mutation abrogated binding of (S)-
ﬂuoxetine. However, the GuaHCl dependency of the A229V
virus required the combination of GuaHCl and (S)-ﬂuoxetine
in the TSA experiment, which may add confounding eﬀects
(Figure 5C).
In summary, mutations at position I227 in the 224AGSINA-
229 loop as well as the C179F and F190L mutations at the
bottom of the binding site A confer resistance to (S)-
ﬂuoxetine, while the V187 M and D245N mutations, which are
more at the edge of the pocket, do not.
2. DISCUSSION
Enteroviruses are a major global health burden, but currently,
no antiviral therapy is available. The high degree of
conservation makes the enterovirus 2C protein an attractive
target for the development of broad-spectrum enterovirus
inhibitors (Supplementary Figure 3). Several compounds,
including a number of repurposed drugs, have been identiﬁed
as inhibitors of enterovirus replication by targeting 2C
(reviewed in ref 2), but to date, the molecular mechanisms
underlying the antiviral eﬀects are lacking. Fluoxetine, one of
the identiﬁed compounds, is an FDA-approved drug that is
used as a highly selective inhibitor of SERT for the treatment
of major depression and anxiety disorders. In this study, we
provide new insights into how the repurposed drug ﬂuoxetine
acts as an antiviral compound against CVB3.
Fluoxetine has one chiral center, and only the S-enantiomer
of ﬂuoxetine has anti-enteroviral activity and binds to 2C in
vitro. In previous studies, the racemic mixture of ﬂuoxetine
inhibited EV-B and EV-D species but not EV-A, EV-C, and
rhinoviruses.33,34 Here, we show that the S-enantiomer, but not
the R-enantiomer, has a clearly increased antiviral potency
compared to the racemic mixture against CVB3 and also EV-
D68, while the cytotoxicity in cell culture is comparable (Table
1). Unexpectedly, we observed that the S-enantiomer also
exerts antiviral activity against rhinoviruses. Presumably, the
antiviral activity of the racemic mixture against rhinoviruses is
so weak that it cannot be separated from the cytotoxicity
eﬀects. We cannot exclude that (S)-ﬂuoxetine would also
inhibit EV-A or EV-C species at even higher concentrations,
but this cannot be tested in the current model systems due to
cytotoxicity. Another explanation for why EV-A and EV-C
species are not sensitive to ﬂuoxetine is that there could be
strain-speciﬁc diﬀerences in the sensitivity toward inhibitors.
For example, we also show that (S)-ﬂuoxetine does not inhibit
EV-A71 (strain BrCr). It is unknown why EV-A71 is resistant
to (S)-ﬂuoxetine; further in-depth investigations are needed to
gain a better understanding of the underlying mechanism of
resistance of EV-A71. However, a diﬀerent EV-A71 strain was
shown to be sensitive to racemic ﬂuoxetine.41 Thus, it is
possible that diﬀerent EV-A and EV-C strains are sensitive
toward (S)-ﬂuoxetine.
The in vivo eﬃcacy of ﬂuoxetine toward enterovirus
infections has until now been relatively poorly studied. Recent
outbreaks of acute ﬂaccid myelitis (AFM) in the US are, at
least in part, associated with EV-D68.50 In a mouse model for
EV-D68 associated paralysis, ﬂuoxetine did not have an eﬀect
on motor impairment of mice or viral load in muscle and spinal
cord but instead seemed to slightly aggravate the disease.51
Because in human AFM cases treatment options other than
supportive care are lacking, several clinicians have tried the oﬀ-
label use of ﬂuoxetine to treat pediatric patients. A
retrospective study of safety and eﬃcacy of ﬂuoxetine to
treat AFM revealed no beneﬁcial eﬀect of ﬂuoxetine.52 Instead,
ﬂuoxetine-treated patients had somewhat more severe
symptoms, suggesting a negative eﬀect of ﬂuoxetine on AFM,
in line with the mouse model.51 However, this retrospective
study had some limitations that make it diﬃcult to draw
deﬁnitive conclusions. For example, patients had been treated
with diﬀerent dosing regimens. Furthermore, ﬂuoxetine
treatment was started only after onset of AFM symptoms
when irreversible neuronal damage may already have been
inﬂicted. Moreover, viral loads were not tested, leaving the
question unanswered whether the virus was still actively
replicating at the time of treatment and, if so, whether
ﬂuoxetine had any eﬀect on viral loads. In contrast, in a
pancreatitis mouse model, the racemic ﬂuoxetine mixture
reduced the levels of CVB4 infectious particles in heart and
pancreas and reduced pancreatitis severity when it was given 1
day prior to CVB4 infection and subsequently every day post-
infection.53 Finally, in a case study of an immunocompromised
child with chronic EV-B induced encephalitis, the oﬀ-label use
of ﬂuoxetine eliminated the virus and led to recovery of the
patient.38 These seemingly opposing results stress the
importance of further in vivo studies of ﬂuoxetine to combat
diﬀerent enteroviruses and treat diﬀerent types of enterovirus-
associated diseases. The plasma concentration of ﬂuoxetine
ranges from 91 to 300 ng/mL after 30 days of dosing 40 mg/
day.54 The metabolite norﬂuoxetine, which also shows antiviral
activity,33 reaches a plasma concentration from 72 to 258 ng/
mL. The slow elimination of ﬂuoxetine together with the
metabolite norﬂuoxetine should reach a suﬃcient plasma
concentration that corresponds with the EC50 in cell culture
(∼1 μM, which corresponds to ∼150 ng/mL).
In contrast to the SSRI activity, leading to the antidepressant
eﬀect of ﬂuoxetine, the 2C-mediated antiviral activity of
ﬂuoxetine is stereoselective, lending further support to the idea
that the antiviral activity is unrelated to the known SSRI
activity of ﬂuoxetine. This implies that, when ﬂuoxetine is used
as an antiviral treatment, any potential SSRI-related side eﬀects
can be reduced by providing only (S)-ﬂuoxetine, which is then
at lower overall concentration. However, when only (S)-
ﬂuoxetine is used, the advantages of drug repurposing of
ﬂuoxetine, which is licensed as a racemic mixture, are nulliﬁed
and new safety studies are needed. Fragment 1, which contains
the 4-(triﬂuoromethyl)benzene moiety and the amino group,
gave the ﬁrst indication for the importance of these chemical
features for the antiviral eﬀect. From there on, structure
activity relationship studies could help to design new
molecules with even a stronger antiviral eﬀect but reduced or
suppressed SERT inhibition.
To investigate the mode-of-action of how ﬂuoxetine binds to
enterovirus 2C, we built a homology model of CVB3 on the
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basis of the crystal structure of the ﬂuoxetine-insensitive EV-
A71 2C. In the predicted binding model, the 4-
(triﬂuoromethyl)benzene group of ﬂuoxetine occupies the
deep hydrophobic pocket close to residues L126, L178, V187,
F190, L238, I227, A229, and F242. Mutational studies to test
the binding hypothesis were designed, and mutations at the
bottom of the predicted pocket reduced (S)-ﬂuoxetine binding
by providing resistance. The mutations on the borders of the
pocket did not confer resistance to (S)-ﬂuoxetine; therefore,
we cannot exclude alternative entrance sites to the hydro-
phobic cavity. Crystallographic data is needed to yield ultimate
clarity about the binding mode.
2C is a member of the SF3 helicases of the AAA+ ATPase
superfamily and contains Walker A and B motifs, which are
important for recognizing the triphosphate of ATP, and a short
motif C that is located on top of Walker B.7 The residues L178
and C179 in the predicted binding pocket are located within
the Walker B motif or immediately thereafter. Furthermore,
the 224AGSINA229 loop, which harbors resistance mutations
and lines the edge of the predicted pocket, is directly C-
terminal to the motif C. Residues L238, F242, and D245 are in
proximity to the arginine ﬁngers (R240 and R241), which play
an important role in the ATPase domain and are required for
ATP hydrolysis. Hence, it is conceivable that ﬂuoxetine inhibits
ATPase activity allosterically through relatively short-range
eﬀects although alternative modes, e.g., through long-range
eﬀects, cannot be excluded. Still, the exact molecular details of
how ﬂuoxetine inhibits the ATPase activity of 2C remain to be
determined.
The 224AGSINA229 loop forms a hot spot for resistance
mutations against ﬂuoxetine and many other 2C inhibitors,
while fewer mutations have been found in the predicted
ﬂuoxetine binding pocket. The residues in the pocket are
evolutionarily highly conserved, implying that there is little
room for variation that could induce resistance in the pocket
residues without aﬀecting virus ﬁtness. In contrast, the 224−
229 loop diverges more between enterovirus species,
suggesting that the loop allows for more sequence diversity
that could yield resistance (Supplementary Figure 3). The
224AGSINA229 loop is conserved between the ﬂuoxetine-
sensitive viruses CVB3 and EV-D68, but the motif diﬀers in
the ﬂuoxetine resistant viruses EV-A71 and poliovirus
(Supplementary Figure 3). The corresponding 224AGSINA-
229 loops might be more rigid in these latter viruses, thereby
interfering with ﬂuoxetine binding. Mutations in the 224-
AGSINA229 loop confer resistance not only against ﬂuoxetine
but also against several other compounds, including TBZE-
029, HBB, MRL-1237, and GuaHCl.29 Resistance mutations
may favor a conformation of the 224AGSINA229 loop in
which the binding pocket is not accessible for ﬂuoxetine
anymore. Furthermore, the mutations may change the
ﬂexibility of the loop in such a way that the inhibitory eﬀect
of ﬂuoxetine is circumvented. Further biophysical studies are
needed to decipher how the resistance mutations aﬀect the
overall stability of the protein or the accessibility of the binding
pocket. However, addressing the possible role of S-ﬂuoxetine
in the hexamerization of 2C is presently not possible because
the production of homogeneous 2C protein in its biologically
relevant oligomerization state has not yet been achieved.
In conclusion, this study sheds new light onto how the 2C
inhibitor ﬂuoxetine may target the enterovirus 2C protein. In
particular, the discovery of the stereoselective activity will fuel
further mode-of-action studies and support the rational design
of novel, ﬂuoxetine-derived broad-spectrum enterovirus
inhibitors.
3. METHODS
3.1. Cells and Reagents. Buﬀalo Green Monkey cells
(BGM) and HeLa R19 cells were cultured in Dulbecco’s
modiﬁed Eagle’s medium (DMEM, Lonza) supplemented with
10% fetal bovine serum (FBS, Lonza). Huh7-Lunet 7/T7, a
stable cell pool expressing T7 RNA polymerase and blasticidin
S-deaminase,55 was cultured in DMEM supplemented with
10% FBS and 10 μg/mL blasticidin (Sigma-Aldrich). All cell
lines were grown at 37 °C in 5% CO2. Guanidine
hydrochloride (GuaHCl) was purchased from Sigma-Aldrich.
A racemic mixture of ﬂuoxetine was purchased from Sigma-
Aldrich. The S- and R-enantiomers were purchased either from
Sigma-Aldrich or Carbosynth. BF738735 was provided by
Galapagos NV.48 Dibucaine was purchased from Sigma-
Aldrich. GuaHCl was dissolved in water at 2 M stock
concentration, and all other compounds were dissolved in
DMSO at 10 mM stock concentration.
3.2. Viruses. EV-A71 (strain BrCr), PV1 (strain Sabin,
ATCC), and EV-D68 (strain Fermon) were obtained from the
National Institute for Public Health and Environment (RIVM)
in The Netherlands. HRV-2 and HRV-14 were obtained from
Joachim Seipelt from the Medical University of Vienna in
Austria. RLuc-CVB3, which contains a Renilla luciferase gene
upstream of the capsid coding region, was obtained by
transfecting Huh7-Lunet 7/T7 cells with MluI-linearized
pRLuc-53CB3/T7 plasmid as described.56 RLuc-encephalo-
myocarditis virus (EMCV, strain mengovirus), encoding a
Renilla luciferase gene upstream of the capsid-coding region,
was described before.42,43 CVB3 (strain Nancy) and CVB3 2C
mutant viruses were obtained by transfecting BGM cells with
RNA transcripts derived from the full-length infectious clones
p53CB3/T7 as described in ref 57. The mutations 2C-
[A224V], 2C[I227V], 2C[A229V], 2C[A224V/I227V], 2C-
[A224V/A229V], 2C[I227V/A229V], 2C[A224V/I227V/
A229V], 2C[C179F], and 2C[F190L] were introduced into
the p53CB3/T7 infectious clone and 2C[V187M] and
2C[D245N] were introduced into the pRLuc-53CB3/T7
using side directed mutagenesis. In vitro transcribed RNA
transcripts were transfected into HeLa R19 cells to obtain
virus. To ensure that the introduced mutations are retained in
the generated virus, viral RNA was isolated with the
NucleoSpin RNA Virus kit (Macherey-Nagel) according to
the manufacturer’s protocol, and the presence of the desired
mutations was conﬁrmed by Sanger sequencing. Virus titers
were determined by end point dilution titration, calculated
according to the method of Reed and Muench,58 and
expressed as 50% cell culture infective dose (CCID50).
3.3. Single-Cycle Virus Infection. Virus infections were
performed by incubating subconﬂuent HeLa R19 cells with
virus at a multiplicity of infection (MOI) of 0.1 at 37 °C for 30
min. Next, the medium was removed, and fresh (compound-
containing) medium was added to the cells. At the indicated
time points, the medium was discarded and cells were lysed.
For measurements of infectious particles, virus was released
from the cells by three freeze−thawing cycles. Virus titers were
determined by the end-point dilution assay and calculated by
the method of Reed and Muench.58 In the case of infection
with RLuc-CVB3 and RLuc-EMCV, cells were lysed 6−7 h
post-infection and the Renilla luciferase Assay System
(Promega) was used to determine the luciferase activity.
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Where indicated, cell viability was determined in parallel using
the AQueous One Solution Cell Proliferation Assay (Promega)
according to the manufacturer’s protocol. Optical density at
490 nm was determined using a microplate reader.
3.4. Multicycle Virus Infection. Subconﬂuent layers of
HeLa R19 cells were seeded in 96-wells and treated with serial
dilutions of the corresponding compounds. Cells were infected
with CVB3 at the lowest possible MOI (MOI of 0.001)
resulting in full CPE within 3 days. Subsequently, the cells
were incubated at 37 °C for 3 days until full CPE was observed
in the virus infected untreated cell controls. Cell viability was
determined in parallel using the AQueous One Solution Cell
Proliferation Assay (Promega) according to the manufacturer’s
protocol. The optical density at 490 nm was determined using
a microplate reader. Raw OD values were converted to the
percentage of untreated and uninfected cell control after
subtraction of the background.
3.5. Binding of Fluoxetine to Recombinant WT and
Mutant 2C Proteins. The DNA fragment coding for CVB3
2C (amino acids 37 to 329) was cloned downstream of a
cleavable thioredoxin-hexahistidine tag. Mutations were
introduced into the 2C coding sequence by PCR-based site-
directed mutagenesis. The recombinant WT and mutant
proteins were produced in Escherichia coli T7 Express (New
England BioLabs) at 17 °C. Protein puriﬁcation and tag
removal were performed under nondenaturing conditions as
previously described.35 The ﬁnal size-exclusion chromatog-
raphy step was performed with a buﬀer containing 10 mM
HEPES and 300 mM NaCl (pH 7.5). The binding of
ﬂuoxetine or corresponding fragments on WT and mutant
2C proteins was monitored by the ﬂuorescence-based thermal
shift assay (TSA) using a Bio-Rad CFX Connect. TSA plates
were prepared by dispensing into each well the 2C protein
(ﬁnal concentration of 15 μM in 50 mM Tris, 300 mM NaCl,
pH 8), which was mixed with 1 μL of fragment or ﬂuoxetine
(from 20 mM stock in 100% DMSO, 1 mM ﬁnal concentration
in 4% DMSO) and a SYPRO orange solution in concentrations
recommended by the manufacturer in a ﬁnal volume of 25 μL.
The experiments were performed under a temperature gradient
ranging from 20 to 95 °C (incremental steps of 0.2 °C/12 s).
The denaturation of the proteins was monitored by following
the increase of the ﬂuorescence emitted by SYPRO orange that
binds exposed hydrophobic regions of the denatured protein.
The melting temperature (Tm) was calculated as the mid-log of
the transition phase from the native to the denatured protein
using a Boltzmann model (Origin software). The reference
unfolding temperature of proteins in 4% DMSO (T0) was
subtracted from the values in the presence of fragment (Tm) to
obtain thermal shifts, ΔTm = Tm − T0.
The binding of (S)- and (R)-ﬂuoxetine to WT CVB3 2C
was further characterized by isothermal titration calorimetry
(ITC) using a MicroCal iTC200 instrument (Malvern).
Experiments were carried out at 20 °C in a solution containing
10 mM HEPES, 300 mM NaCl, and 0.8% DMSO (pH 7.5).
The 2C protein concentration in the cell was 80 μM whereas
the ﬂuoxetine concentration in the syringe was 400 μM. For
(R)-ﬂuoxetine, two injections were necessary. Heats of dilution
were measured by injecting the ligand into the protein
solution. Titration curves were ﬁtted by using MicroCal Origin
software, assuming one set of sites, and enthalpy changes
(ΔH), dissociation equilibrium constants (Kd), and stoichi-
ometry were extracted.
3.6. Molecular Modeling. The computational studies
were carried out on a 1.80 GHz Intel Xeon (8 cores)
processor-based system, running Ubuntu 14.04 LTS, using a
Molecular Operating Environment (MOE) 2015.10 (Chemical
Computing Group Inc. 2016) and Maestro v11.4 (Schrödinger
LLC, New York, NY, 2017). The homology model was
generated with an MOE using an integrated sequence
alignment and structure preparation tools for the template.
Preparation of the structure for docking and molecular
dynamic simulations and subsequent data analysis were carried
out with Maestro. Docking experiments were performed using
the GlideSP module in Maestro, running the default settings.
The molecular dynamics simulations were performed using the
Desmond package (Desmond Molecular Dynamics System, D.
E. Shaw Research, New York, NY, 2018; Maestro-Desmond
Interoperability Tools, Schrödinger, New York, NY, 2018).
Pictures of molecular modeling were prepared using MOE.
3.7. Homology Modeling. The protein sequence of
CVB3 (strain Nancy) 2C protein was downloaded from
Uniprot (ID: P03313 amino acids 1101−1429). The structures
reported in ref 39, especially 5GRB, were used as a starting
point in this study and were retrieved from the Protein Data
Bank. 5GRB contains ATPγS and was the structure used for
the computational studies. The sequence of CVB3 was aligned
to the sequence of the crystallized EV-A71 using MOE. 5GRB
chain A was used as a structural template for the homology
model. The homology model was built with the Amber12:
EHT force ﬁeld.59,60 Automatic detection of disulﬁde bridges
was disabled. Ten intermediate models were generated and
reﬁned using a medium reﬁnement by molecular mechanics
(highly tethered minimization to relieve steric strains). The
ﬁnal model was calculated using Coulomb and Generalized
Born/Volume Integral (GB/VI) interaction energies61 and was
not further reﬁned.
After the generation of the homology model, the structure
was revised using the Structure Preparation function in MOE.
In order to further evaluate the quality of the homology model
for future studies, the phi/psi angles were analyzed in the
Ramachandran plot using the Protein Geometry tool of MOE.
Identiﬁed outliers were investigated and, if relevant, corrected
manually. Then, the validation of the model was carried out
using RAMPAGE Ramachandran plot analysis.62 Amino acid
environment analysis was carried out using the SAVES server
v3.0 (http://servicesn.mbi.ucla.edu/SAVES/) comprising Ver-
ify 3D.63−66
3.8. Site Finder. The site identiﬁcation tool Site Finder,
which comprised the software suite MOE, was run on the
prepared CVB3 homology model to identify possible active
sites for the known 2C targeting compounds. Two binding
pockets (termed site A and site B) were selected on the basis
of their vicinity to known mutations in the 224AGSINA229
loop that convey resistance against several known 2C
inhibitors including ﬂuoxetine.29,34,35 For both pockets, a set
of dummy atoms was created in the positions of the alpha
spheres that are used to determine pockets in Site Finder.
3.9. Docking. After the identiﬁcation of site A and site B,
both the compounds and the protein were prepared for the
docking with Glide. The homology model of CVB3 was
prepared with the Protein Preparation Wizard embedded in
Maestro. For each binding site, a grid box for the positioning of
the molecules during the docking was generated setting the
centers of the boxes to the coordinates of representative
dummy atoms generated by Site Finder. The stereochemistry
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on the chiral center of ﬂuoxetine was deﬁned using the
molecule builder in MOE, and the two enantiomers were saved
in separate .sdf ﬁles. Both of them were subjected to the ligand
preparation protocol (ligprep) in Maestro creating up to 32
conformations each. Then, all conformations obtained for (R)-
and (S)-ﬂuoxetine were docked with Maestro Glide in
standard precision (SP) mode into each binding site. The
poses were inspected for their ﬁt within the pockets and their
interactions with the protein. The best protein−ligand
complexes for each site and each enantiomer were saved and
prepared for molecular dynamics (MD) simulations.
3.10. Molecular Dynamics Simulations. All MD
simulations were performed using Desmond, part of the
Maestro v11.4 simulation package (Schrödinger LLC, New
York, NY, 2017). OPLS3 was used as the force ﬁeld. The
complexes of (R)-ﬂuoxetine and (S)-ﬂuoxetine docked to 2C
of CVB3 were placed in a cubic box (buﬀer 10 Å) using the
TIP3P water model. The negative charges on the protein were
neutralized adding Na+ atoms to the system. Magnesium
chloride (10 mM) was added to the box to simulate
physiological conditions. Before the MD simulation, the
system was ﬁrst equilibrated for 112 ps at 10 K in an NVT
ensemble and then simulated for 48 ps at a constant pressure
of 1 atm using the NPT ensemble. All MD simulations were
performed for 100 ns at constant temperature (300 K) and
pressure recording snapshots every 160 ps.
The estimated ΔGbinding was calculated using the Desmond
command-line script thermal_mmgbsa.py. After splitting the
trajectory ﬁle of the MD simulation into snapshots, the script is
calculating the average computed binding energy of the ligand
(Table 2 and Supplementary Figure 2).
3.11. Chemistry. All solvents and reagents used were
obtained from commercial sources unless otherwise indicated.
All reactions were performed under a nitrogen atmosphere. 1H
and 13C NMR spectra were recorded with a Bruker Avance
DPX500 spectrometer operating at 500 MHz for 1H and 125
MHz for 13C with Me4Si as internal standard. Deuterated
dimethyl sulfoxide (DMSO) was used as the solvent for NMR
experiments. 1H chemical shift values (δ) are referenced to the
residual nondeuterated components of the NMR solvents (δ =
2.50 ppm for DMSO). The 13C chemical shifts (δ) are
referenced to DMSO (central peak, δ = 39.5 ppm). Thin layer
chromatography (TLC) was performed on Silica gel plates
(Merck Kieselgel 60 F254), which were developed by the
ascending method. Column chromatography was performed
on an Isolera Biotage system. Purity of synthesized compounds
was determined by UPLC-UV-MS analysis (Waters UPLC
system with both Diode Array detection and Electrospray
(+’ve and −’ve ion) MS detection). The purity of all
compounds was determined to be >95% by UPLC using the
eluents H2O containing 0.1% triﬂuoroacetic acid (eluent A)
and acetonitrile containing 0.1% triﬂuoroacetic acid (eluent B)
at the following conditions: Waters Acquity UPLC BEH C18,
1.7 μm, 2.1 × 50 mm column; 0.5 mL/min; column
temperature, 40 °C; sample diluent, acetonitrile; sample
concentration, 10 μg/mL; injection volume, 2 μL; gradient,
90% eluent A (0.1 min), 90−0% eluent A (1.5 min), 0% eluent
A (1.4 min), and 90% eluent A (0.1 min) (method 1).
3.12. Synthesis of 1-(3-Bromopropoxy)-4-
(triﬂuoromethyl)benzene (Intermediate). To a solution
of 1,3-dibromopropane (6.17 mmol) and potassium carbonate
(4.63 mmol) in DMF (3 mL), 4-(triﬂuoromethyl)phenol (3.08
mmol) in DMF (1.2 mL) was added dropwise; the reaction
mixture was stirred at room temperature for 2 h and then
heated to 70 °C for 2 h. The mixture was ﬁltrated, diluted with
ethyl acetate (10 mL), and washed with water (3 × 10 mL).
The organic layer was dried over sodium sulfate and
evaporated under reduced pressure. The residue was puriﬁed
by ﬂash column chromatography and eluted with n-hexane/
EtOAc (100:0 v/v) increasing to n-hexane/EtOAc (70:30 v/
v). 207 mg of 1-(3-bromopropoxy)-4-(triﬂuoromethyl)-
benzene was obtained in 47% yield as a yellow oil. 1H NMR
(DMSO) δ 7.65 (d, J = 8.7 Hz, 2H), 7.14 (d, J = 8.7 Hz, 2H),
4.17 (t, J = 6.0 Hz, 2H), 3.68 (t, J = 6.6 Hz, 2H), 2.28 (p, J =
6.3 Hz, 2H). 19F NMR (DMSO) δ −59.83 (s, 3F). 13C NMR
(DMSO) δ 161.67, 127.44 (m), 125.02 (q, J = 271.0 Hz),
121.73 (q, J = 32.1 Hz), 115.44, 32.08, 31.50.
3.13. Synthesis of Fragment 1: N-Methyl-3-(4-
(triﬂuoromethyl)phenoxy)propan-1-amine. To a round-
bottom ﬂask containing methylamine in absolute ethanol (2
mL) cooled to 0 °C, a solution of 1-(3-bromopropoxy)-4-
(triﬂuoromethyl)benzene (0.80 mmol) in absolute EtOH (0.8
mL) was added dropwise. The reaction mixture was stirred at
room temperature overnight. The mixture was ﬁltrated. The
obtained residue was dissolved in DCM (10 mL). The organic
layer was washed with saturated aqueous NaHCO3 and brine,
dried over Na2SO4, and concentrated in vacuo. The residue was
treated with HCl in diethyl ether. The resulting solid was then
ﬁltered and washed with diethyl ether to give 131 mg of N-
methyl-3-(4-(triﬂuoromethyl)phenoxy)propan-1-amine hydro-
chloride salt as a white powder in a yield of 69%. 1H NMR
(DMSO) δ 8.65 (s, 2H), 7.68 (d, J = 8.6 Hz, 2H), 7.13 (d, J =
8.6 Hz, 2H), 4.16 (t, J = 6.1 Hz, 2H), 3.06 (d, J = 7.4 Hz, 2H),
2.58 (s, 3H), 2.13−2.04 (m, 2H). 19F NMR (DMSO) δ
−59.78. 13C NMR (DMSO) δ 161.58, 127.43 (q, J = 3.7 Hz),
125.02 (q, J = 271.1 Hz), 121.76 (q, J = 32.2 Hz), 115.48,
65.58, 46.14, 33.07, 25.71. UPLC: retention time = 1.521 min,
MS [ESI, m/z]: 234.1 [M + Na]+.
3.14. Synthesis of Fragment 2: N-Methyl-3-phenyl-
propan-1-amine. To a round-bottom ﬂask containing
methylamine in absolute ethanol (2.18 mL), a solution of
(3-bromopropyl)benzene (1.25 mmol) in absolute EtOH
(0.87 mL) was added dropwise at 0 °C. The reaction mixture
was stirred at room temperature overnight. The solid residue
was ﬁltered and washed with absolute EtOH to give 195 mg of
N-methyl-3-phenylpropan-1-amine in a yield of 75% as a white
powder. 1H NMR (DMSO) δ 8.48 (s, 2H), 7.35−7.27 (m,
2H), 7.26−7.17 (m, 3H), 2.91−2.85 (m, 1H), 2.65 (t, J = 7.7
Hz, 2H), 2.55 (s, 3H), 1.94−1.85 (m, 2H). 13C NMR
(DMSO) δ 141.13, 128.92, 128.73, 126.57, 48.30, 32.88,
32.32, 27.57.
3.15. Synthesis of Fragment 4: 1-(Benzyloxy)-4-
(triﬂuoromethyl)benzene. To a solution of 4-
(triﬂuoromethyl)phenol (1.233 mmol), in DMF (3 mL),
1.553 mmol of (bromomethyl)benzene (1.553 mmol) and
potassium carbonate (4.932 mmol) were added. The obtained
mixture was stirred at 105 °C for 4 h. After the reaction
completion, the mixture was ﬁltrated, diluted with ethyl acetate
(10 mL), and washed with water (3 × 10 mL). The organic
layer was dried over sodium sulfate and evaporated under
reduced pressure. The residue was puriﬁed by ﬂash column
chromatography and eluted with n-hexane/DCM (100:0 v/v
increasing to 0:100 v/v), obtaining 212 mg of 1-(benzyloxy)-4-
(triﬂuoromethyl)benzene in a yield of 75% as a white powder.
1H NMR (DMSO) δ 7.66 (d, J = 8.5 Hz, 2H), 7.49−7.44 (m,
2H), 7.44−7.38 (m, 2H), 7.38−7.32 (m, 1H), 7.20 (d, J = 8.5
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Hz, 2H), 5.20 (s, 2H). 19F NMR (DMSO) δ −59.81. 13C
NMR (DMSO) δ 161.64, 136.88, 128.98, 128.50, 128.25,
127.42 (q, J = 3.7 Hz), 125.02 (q, J = 271.1 Hz), 121.74 (q, J =
32.1 Hz), 115.77, 70.00.
3.16. Purchased Fragments. Fragment 3 (3-(methyl-
amino)-1-phenylpropan-1-ol) and fragment 6 (4-
(triﬂuoromethyl)phenol) were purchased from Sigma-Aldrich;
they possess a purity grade of >97% and were used as received.
Fragment 3 was obtained as a racemic mixture. Fragment 5 (4-
(triﬂuoromehtyl)anisol) was ordered from Alfa Aesar (>98%
pure). The fragments were dissolved in DMSO at a stock
concentration of 100 mM.
3.17. Calculations. The concentration of the compound
that inhibits virus-induced cell death by 50% (50% eﬀective
concentration [EC50]) was calculated by nonlinear regression
analysis. Cytotoxicity of the compounds was assessed in a
similar setup, and 50% cytotoxic concentration (CC50) values
were derived from cell viability values determined with an
MTS assay. Each experiment was performed at least in
triplicate. The nonlinear regression and the graphs were made
with GraphPad Prism Version 6.
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